Informations générales (source: ClinicalTrials.gov)
Study of Metabolic Changes in the Transformation Malignant Precancerous Skin Lesions (MITOSKIN)
Interventional
N/A
University Hospital, Bordeaux (Voir sur ClinicalTrials)
février 2020
décembre 2022
02 novembre 2024
Skin carcinomas are the most frequent cancers in the world, including basal cell
carcinomas and cutaneous squamous cell carcinoma (cSCCs), with more than 60.000 new
annual cases in France. Their incidence increases mainly due to ultraviolet (UV) exposure
and population ageing. Then from 1994 to 2006, the incidence of cSCC has increased by
300%. CSCCs typically manifests as a spectrum from a precursor actinic keratosis (AK) -
possible spontaneous regression at this stage- to in situ cSCC invasive cSCC and finally
metastatic cSCC.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Hôpital Saint-André - CHU de Bordeaux - 33000 - Bordeaux - France | Marie BEYLOT-BARRY, MD, PhD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Every patient with suspected lesion :
- AK,
- in situ cSCC,
- infiltrative cSSC
- cSCC with recurrent disease
- cSCC with cutaneous metastases.
- Patients 18 years of age or older,
- Patients with suspected AK or BCC lesions (in situ, infiltrating or metastatic),
- Patient able to sign a consent form,
- Patient affiliated with a Social Security system.
- Every patient with suspected lesion :
- AK,
- in situ cSCC,
- infiltrative cSSC
- cSCC with recurrent disease
- cSCC with cutaneous metastases.
- Patients 18 years of age or older,
- Patients with suspected AK or BCC lesions (in situ, infiltrating or metastatic),
- Patient able to sign a consent form,
- Patient affiliated with a Social Security system.
- Prior systemic treatment such as checkpoint inhibitors or chemotherapy.
- Patients with cSCC or AK localized on visible zone of the face or folds